Could an arthritis drug lift the fog of depression?
NCT ID NCT07003997
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This study tests whether baricitinib, a drug that blocks JAK signaling, can improve motivation and brain function in people with major depression who have high inflammation. About 100 adults aged 25-55 with depression and elevated C-reactive protein will receive the drug or placebo for 8 weeks. The goal is to see if reducing inflammation helps restore reward and movement-related brain connections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Conditions
Explore the condition pages connected to this study.